ReviewCancers2023
Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Targeted Therapy, Immunotherapy, and Molecular Testing in Advanced Solid Tumors: A Medicare Analysis.Cancer medicine · 2026Observational
- Identifying a Critical Blind Spot: How Commercial AI (CAD) Systems Fail to Detect Faint Ground-Glass Opacities at -730 HU on Low-Dose CT.Diagnostics (Basel, Switzerland) · 2026Article
- Surgical Aspects of Treatment of the Lung Cancer Found in Low-Dose CT-Based Screenings.Journal of clinical medicine · 2026Article
- Lung cancer masquerading in the background of bronchiectasis: a report of two cases and literature review.Frontiers in oncology · 2026Article
- A novel composite model for distinguishing benign and malignant pulmonary nodules.Clinical and experimental medicine · 2025Article
- Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study.International journal of molecular sciences · 2025Article
- Artificial Intelligence and Early Detection of Breast, Lung, and Colon Cancer: A Narrative Review.Cureus · 2025Review
- Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review.Cancer metastasis reviews · 2024Review
- The clinical effect of thoracoscopic segmentectomy in the treatment of lung malignancies less than 2CM in diameter.Journal of cardiothoracic surgery · 2024Article
- Nanoscale Extracellular Vesicle-Enabled Liquid Biopsy: Advances and Challenges for Lung Cancer Detection.Micromachines · 2024Review
- Detecting mir-155-3p through a Molecular Beacon Bead-Based Assay.Molecules (Basel, Switzerland) · 2024Article
- Medical Relevance, State-of-the-Art and Perspectives of "Sweet Metacode" in Liquid Biopsy Approaches.Diagnostics (Basel, Switzerland) · 2024Review
- Description of an activity-based enzyme biosensor for lung cancer detection.Communications medicine · 2024Article
- Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- Clinical Network Systems Biology: Traversing the Cancer Multiverse.Journal of clinical medicine · 2023Review
- Understanding the public knowledge, attitude, and practice toward screening and risk factors of lung cancer in Saudi Arabia: A cross-sectional study.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of lung cancer has transformed over the past decade and is no longer considered a singular disease as it now has multiple sub-classifications based on molecular markers. The current treatment paradigm requires a multidisciplinary approach. One of the most important facets of lung cancer outcomes however relies on early detection. Early detection has become crucial, and recent effects have shown success in lung cancer screening programs and early detection. In this narrative review, we evaluate low-dose computed tomography (LDCT) screening and how this screening modality may be underutilized. The barriers to broader implementation of LDCT screening is also explored as well as approaches to address these barriers. Current developments in diagnosis, biomarkers, and molecular testing in early-stage lung cancer are evaluated as well. Improving approaches to screening and early detection can ultimately lead to improved outcomes for patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.